Abstract

Subcutaneous semaglutide, delivered by a single-dose pen-injector at a maintenance dose of 2.4mg once weekly, is approved in the USA for weight management in people with a body mass index (BMI) of 30 kg/m2 or higher, or with a BMI of 27 kg/m2 or higher and a minimum of one obesity-related co-morbidity. The semaglutide single-dose pen-injector could be a shield-activated auto-injector. Auto-injectors were at the start developed for emergency use however are used for chronic conditions for many years and for glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment for type 2 diabetes disease (T2D) since 2014. Shield activation entails the discharge of the injection by pushing the pen-injector against the patient's skin, as hostile activation via a button.

Keywords: Subcutaneous semaglutide, pen-injector